Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

CLC.2 (A041202) - A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> = to 65 years of age) with Chronic Lymphocytic Leukemia (CLL).

CLC.2E - A Prospective Economic Analysis of CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia

These trials were closed to accrual on May 1, 2016.

Thanks to all participating centres, staff and patients for participating!